Sign in

Abstract

Understanding how epigenetic mechanisms shape metastatic dissemination and therapy response in ovarian high-grade serous carcinoma (HGSC) has been hindered by the absence of large, anatomically diverse, and longitudinal datasets. Here, we present a comprehensive resource of the HGSC methylome, comprising 404 whole-genome bisulfite sequenced samples from 125 patients belonging to the real-world DECIDER trial. Tumor-specific methylomes were integrated with matched RNA sequencing, whole-genome sequencing and clinical outcomes, which enabled identification of > 8,500 regulatory promoters. Our results show that the regulatory methylome is largely established early in tumor progression and remains stable through chemotherapy. Tumors with poor response to treatment are marked by widespread promoter hypermethylation, particularly cancer cells in ascites, leading to epigenetic silencing of pathways targeted by chemotherapy agents. Our proof-of-principle analysis shows that these epigenetic signatures are detected in plasma-derived DNA, highlighting the value of DNA methylation in liquid biopsy-based disease monitoring. This study provides a foundational resource for dissecting the spatial and temporal dynamics of cancer methylomes and establishes a framework for integrating epigenetic states with clinical trajectories in HGSC.

PDFDOI

02 /Specification & Classification

Click any tag to browse matching papers

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISGull '20Farid '26Bonito '19Zhang '25Riso '18Yu '22
71% semantic matchGenomics
Nicole Gull, Michelle R. Jones, Pei-Chen Peng+18 more·bioRxiv·Aug 25, 2020· 2 citations